Co-Diagnostics Inc.

8.87-0.0300-0.34%Vol 100.79K1Y Perf -34.87%
Apr 23rd, 2021 10:36 DELAYED
BID8.85 ASK8.90
Open8.79 Previous Close8.90
Pre-Market- After-Market-
 - -%  - -
Target Price
18.00 
Analyst Rating
Strong Buy 1.00
Potential %
102.93 
Finscreener Ranking
★★★★★     69.24
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★★★     70.93
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★★     94.69
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap254.27M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
4.37 
Earnings Date
13th May 2021

Today's Price Range

8.718.97

52W Range

7.8630.99

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.34%
1 Month
-34.61%
3 Months
-24.32%
6 Months
-28.57%
1 Year
-34.87%
3 Years
349.49%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CODX8.87-0.0300-0.34
AAPL133.391.45001.10
GOOG2 290.7922.87001.01
MSFT258.671.50000.58
XOM55.810.54000.98
WFC43.660.96002.25
JNJ165.240.06000.04
FB298.051.53000.52
GE13.600.19001.42
JPM149.562.19001.49
Earnings HistoryEstimateReportedSurprise %
Q04 20200.490.43-12.24
Q03 20200.540.53-1.85
Q02 20200.610.43-29.51
Q01 2020-0.04-0.05-25.00
Q04 2019-0.08-0.10-25.00
Q03 2019-0.08-0.10-25.00
Q02 2019-0.03-0.08-166.67
Q01 2019-0.08-0.09-12.50
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.20-56.52Negative
6/2021 QR0.17-63.83Negative
12/2021 FY0.74-58.66Negative
12/2021 FY1.790.00-
Next Report Date13th May 2021
Estimated EPS Next Report0.20
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume100.79K
Shares Outstanding28.67M
Trades Count895
Dollar Volume18.75M
Avg. Volume1.46M
Avg. Weekly Volume640.05K
Avg. Monthly Volume1.21M
Avg. Quarterly Volume1.46M

Co-Diagnostics Inc. (NASDAQ: CODX) stock closed at 8.9 per share at the end of the most recent trading day (a 2.18% change compared to the prior day closing price) with a volume of 690.46K shares and market capitalization of 254.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 39 people. Co-Diagnostics Inc. CEO is Dwight H Egan.

The one-year performance of Co-Diagnostics Inc. stock is -34.87%, while year-to-date (YTD) performance is -4.3%. CODX stock has a five-year performance of %. Its 52-week range is between 7.86 and 30.99, which gives CODX stock a 52-week price range ratio of 4.37%

Co-Diagnostics Inc. currently has a PE ratio of 6.20, a price-to-book (PB) ratio of 3.81, a price-to-sale (PS) ratio of 3.46, a price to cashflow ratio of 8.80, a PEG ratio of 2.32, a ROA of 115.35%, a ROC of 99.37% and a ROE of 123.87%. The company’s profit margin is 59.94%, its EBITDA margin is 52.90%, and its revenue ttm is $73.00 Million , which makes it $2.55 revenue per share.

Of the last four earnings reports from Co-Diagnostics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $0.20 for the next earnings report. Co-Diagnostics Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Co-Diagnostics Inc. is Strong Buy (1), with a target price of $18, which is +102.93% compared to the current price. The earnings rating for Co-Diagnostics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Co-Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Co-Diagnostics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.80, ATR14 : 1.15, CCI20 : -57.20, Chaikin Money Flow : -0.19, MACD : -1.60, Money Flow Index : 45.59, ROC : -3.99, RSI : 46.78, STOCH (14,3) : 45.20, STOCH RSI : 0.78, UO : 41.65, Williams %R : -54.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Co-Diagnostics Inc. in the last 12-months were: Dwight H Egan (Option Excercise at a value of $296 500), Dwight H Egan (Sold 172 396 shares of value $1 835 965 ), Eugene Durenard (Option Excercise at a value of $116 750), Eugene Durenard (Sold 120 500 shares of value $2 020 945 ), James Nelson (Sold 12 500 shares of value $126 631 ), Reed L. Benson (Option Excercise at a value of $110 000), Reed L. Benson (Sold 89 524 shares of value $940 002 ), Richard S. Serbin (Option Excercise at a value of $233 500), Richard S. Serbin (Sold 127 000 shares of value $2 100 650 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Moderate Buy
2.00
Moderate Buy
2.00

Co-Diagnostics Inc.

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.

CEO: Dwight H Egan

Telephone: +1 801 438-1036

Address: 2401 South Foothill Drive, Salt Lake City 84109, UT, US

Number of employees: 39

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

52%48%

Bearish Bullish

50%50%

News

Stocktwits